New Patent Expands Nanogen's Core Nanotechnology Position Nanofabrication and Nanomanufacturing Applications Claimed



    SAN DIEGO, Sept. 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:  
 NGEN), developer of advanced diagnostic products, announced today that it
 has been granted United States Patent No. 7,060,224 from the U.S. Patent
 and Trademark Office for an application of its core technology in
 nanofabrication and nanomanufacturing. Potential uses of the technology
 range from further miniaturization of the company's microarray testing
 platforms to potential applications in integrated electronics and
 photonics, photovoltaics, fuel cells, and batteries.
     (Logo: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGO)
     "The '224 patent demonstrates the underlying strength and robustness of
 our basic electronic microarray technology and our commitment to continuing
 fundamental R&D to protect our strong IP position in the nascent and
 growing field of nanotechnology," said Howard C. Birndorf, Nanogen chairman
 and chief executive officer.
     Covered by the patent are nanofabrication applications of Nanogen's
 proprietary "electronic addressing" microarray employed in the company's
 NanoChip(R) 400 system for molecular diagnostic applications. The patent
 describes a technology by which both nanoscale and microscale components
 can be manipulated and selectively positioned to achieve a desired
 structure in a rapid and cost-effective manner. The non-mechanical "pick
 and place" technology allows the placement of components at targeted
 positions on a microarray template which can then be linked together in a
 specific and directed manner.
     "It's currently relatively easy to make various types of nanoparticles,
 but it's hard to put different kinds of nanoparticles and other
 nanocomponents together," said Michael J. Heller, a co-founder of Nanogen
 and professor of electrical and computer engineering and bioengineering at
 the University of California, San Diego. "And it's even harder to combine
 nanoparticles with components of other size scales, like you would need to
 do in order to build an integrated sensor device, for example, that could
 circulate within the body, detecting disease and releasing medication as
 appropriate. The non-mechanical 'pick and place' allows for this type of
 integrated assembly."
     Nanogen has an extensive portfolio of intellectual property relating to
 integrated assembly of molecular structures through the use of electric
 field microfabrication technology. The '224 patent builds on that portfolio
 and relates specifically to a process in which nano, micro and macro
 components are attached to one another through solder reflow following
 electroosmostic positioning.
     The technology is particularly applicable to manufacturing of
 photovoltaic devices, fuel cells and batteries, as well as various
 hybrid-integrated components including flat panel displays, wireless/RF
 integrated devices, lab on a chip devices, microcantilever sensor devices,
 atomic force microscope devices, integrated MEMS/optical/microelectronic
 devices, integrated microscopic analytical and diagnostic devices, and
 compact, handheld medical diagnostic devices and systems. The technology
 can also be used to manufacture the company's core microarray testing
 platforms.
     "Fabricating complex integrated devices right now usually requires that
 each component be built separately and then assembled. Interfaces that
 integrate function across the various components can be difficult to
 achieve," said Heller. "Using the non-mechanical 'pick and place'
 technology described in the '224 patent facilitates integrated assembly of
 these complex structures."
     For information about licensing opportunities, contact Nanogen.
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose,
 and ultimately help treat disease. The company's products include real-time
 PCR reagents, the NanoChip(R) electronic microarray platform and a line of
 rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering
 research involving nanotechnology holds the promise of miniaturization and
 continues to be supported for its potential for diagnostic and biodefense
 applications. For additional information please visit Nanogen's website at
 www.nanogen.com.
     Nanogen Forward-Looking Statement
     This press release contains forward-looking statements that are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements,
 including whether patents owned or licensed by Nanogen will be developed
 into products, whether the patents owned by Nanogen offer any protection
 against competitors with competing technologies, whether products under
 development can be successfully developed and commercialized, whether
 results reported by our customers or partners can be identically
 replicated, and other risks and uncertainties discussed under the caption
 "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or
 Form 10-Q most recently filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof. Nanogen
 disclaims any intent or obligation to update these forward-looking
 statements.
 
 

SOURCE Nanogen, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.